Announcements Trials
Browse Landscape

Phase

Phase 2 38Phase NA 17Phase 3 14Phase 1/2 12Phase 1 12Phase EARLY_PHASE1 5Phase 4 2Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 59Precursor Cell Lymphoblastic Leukemia-Lymphoma 44Leukemia 29Hematologic Neoplasms 23Myelodysplastic Syndromes 18Lymphoma 16Neoplasms 15Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12Lymphoma, Non-Hodgkin 9Leukemia, Lymphocytic, Chronic, B-Cell 7Graft vs Host Disease 7Neoplasms by Site 6Neoplasms by Histologic Type 6Multiple Myeloma 6Anemia, Refractory, with Excess of Blasts 6Recurrence 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms, Plasma Cell 5Neoplasm, Residual 5Leukemia, Biphenotypic, Acute 5Infections 5Primary Myelofibrosis 4Lymphoproliferative Disorders 4Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myeloid, Accelerated Phase 4Glioma 4Congenital Abnormalities 4

Interventions

venetoclax 1cedazuridine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Hematologic Diseases × Other hematologic neoplasm × Clear all
NCT04256317 2026-04-30

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Taiho Oncology, Inc.

Phase 2/3 Recruiting
316 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡